DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Immune checkpoint
Immune checkpoint
Selectins in Cancer Immunity
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
5.01.591 Immune Checkpoint Inhibitors
LAG-3: from Molecular Functions to Clinical Applications
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
TNF and Immune Checkpoint Inhibition: Friend Or Foe for Lung Cancer?
Lymphocyte-Activation Gene 3 (LAG-3) Immune Pathway
Current Trends in Cancer Immunotherapy
Immune Checkpoint Molecules B7-H6 and PD-L1 Co-Pattern the Tumor Inflammatory Microenvironment in Human Breast Cancer
The Blockade of Immune Checkpoints in Cancer Immunotherapy
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer
Targeting TRAIL-Rs in KRAS-Driven Cancer Silvia Von Karstedt 1,2,3 and Henning Walczak2,4,5
Immuno-Metabolism: the Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance
Immune Checkpoint Receptors
Serum Soluble Interleukin-2 Receptor As a Potential Biomarker for Immune-Related Adverse Events
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Comprehensive Analysis of Cancers of Unknown Primary for the Biomarkers of Response to Immune Checkpoint Blockade Therapy
The Circulating Soluble Form of the CD40 Costimulatory Immune Checkpoint Receptor and Liver Metastasis Risk in Rectal Cancer
Top View
Immune Checkpoint Molecules in Natural Killer Cells As Potential Targets for Cancer Immunotherapy
Cancer Immunotherapy: Immune Checkpoint
JAK2, PD-L1, and PD-L2 (9P24.1) Amplification in Metastatic Mucosal and Cutaneous Melanomas with Durable Response to Immunothera
How Immunotherapy Is Used to Treat Cancer
Immune Checkpoint Reagents Brochure
Immune Checkpoint Inhibitors Work and What to Expect
Proliferative Potential and Resistance to Immune Checkpoint Blockade in Lung Cancer Patients Sarabjot Pabla1, Jeffrey M
CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
The Effects of Checkpoint Blockade and a CD40 Agonist on T
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Detection of Immune Checkpoint Receptors &Ndash
Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
The Efficacy and Safety of Combination of PD-1 and CTLA-4 Inhibitors: a Meta-Analysis
Immunotherapy Side Effects: Immune Checkpoint Inhibitors, 2020 1 About
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
(SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events
Detection of Soluble Immune Checkpoint Molecules with Procartaplex Panels
Challenges of NK Cell-Based Immunotherapy in the New Era
Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 Are Blocked by Rhus Verniciflua Stokes and Its Active Compounds
Snapshot: Immune Checkpoint Inhibitors
Expression of Immune Checkpoint Receptors on Peripheral Blood Immune Cells Using a 10-Color Assay on the BD Facslyric™ Flow Cytometer
Agonist Redirected Checkpoint, PD1-Fc-OX40L, for Cancer
Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era Ryan J
Central Nervous System Toxicities of Anti-Cancer Immune Checkpoint Blockade Jonathan T
Targeting Selectins, Siglecs and Mammalian Glycans
Quantifying the Efficacy of Checkpoint Inhibitors on CD8+ Cytotoxic T Cells for Immunotherapeutic Applications Via Single-Cell I
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
The Promising Immune Checkpoint LAG-3: from Tumor Microenvironment to Cancer Immunotherapy
Closed System RT-Qpcr As a Potential Companion Diagnostic Test for Immunotherapy Outcome in Metastatic Melanoma Swati Gupta1, Leena Mccann2, Yvonne G
CTLA-4 Fact Sheet
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
PD-L1:CD80 Heterodimer Triggers CD28 While Repressing
Hallmarks of Response to Immune Checkpoint Blockade
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Checking Autoimmune Genetic Risk to Stratify Immune Checkpoint Inhibitor Responders COMMENTARY Animesh A
Agonistic CD40 Antibodies in Cancer Treatment
Modulation of NK Cells with Checkpoint Inhibitors in the Context of Cancer Immunotherapy
Immune Checkpoint Therapy Modeling of PD-1/PD-L1 Blockades Reveals Subtle Difference in Their Response Dynamics and Potential Synergy in Combination
Human CD86 / B7-2 Recombinant Protein (His Tag)
Management of the Adverse Effects of Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor Associated Myocarditis: Pathophysiology
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’S a Charm
Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles
Natural Killer Cell-Related Gene Signature Predicts Malignancy of Glioma and the Survival of Patients
Mechanisms of Resistance to Immune Checkpoint Inhibitors
TNF Blockade Uncouples Toxicity from Antitumor Efficacy Induced with CD40 Chemoimmunotherapy
A Combination of the Activation Marker CD86 and the Immune Checkpoint
CTLA-4 and PD-L1/PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma
The CD40-CD40L Dyad As Immunotherapeutic Target in Cardiovascular Disease
Immune Suppression by PD-L2 Against Spontaneous and Treatment-Related Antitumor Immunity
Mir-424(322) Reverses Chemoresistance Via T-Cell Immune Response Activation by Blocking the PD-L1 Immune Checkpoint